Home/Pipeline/CLN-619

CLN-619

Solid Tumors

Phase 1Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active

Company

Cullinan Therapeutics

About Cullinan Therapeutics

Cullinan Therapeutics is a clinical-stage biopharma focused on translating deep immunology expertise into high-impact therapies for autoimmune diseases and cancer. The company employs a disciplined 'thriller or killer' portfolio strategy, yielding a focused pipeline of novel bispecific T cell engagers and kinase inhibitors. Recent milestones include completing a rolling NDA submission for zipalertinib in EGFR exon 20 NSCLC and reporting promising early clinical data for its bispecific candidates in hematology and autoimmune indications, positioning 2025 as a catalyst-rich year.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed
Undisclosed Whole Cell Vaccine Program(s)	Neuvogen	Pre-clinical	Active
SY-5609	Syros Pharmaceuticals	Phase 1/2	Discontinued
Not Specified (TCR Therapy)	T-Cure Bioscience	Phase 1	Active
B7-H3 Program	Ocean Biomedical	Discovery	Active